-- 根据周二提交给香港交易所的公告，深圳高速公路（港交所代码：0548，沪交所代码：600548）第一季度归属于股东的净利润为5.093亿元人民币，较上年同期的4.78亿元人民币增长7%。 该公司在香港上市的股票周三早盘上涨近1%，而在上海上市的股票则小幅下跌。 每股收益从上年同期的0.203元人民币降至0.192元人民币。 营收从上年同期的17.7亿元人民币小幅下降0.7%至17.6亿元人民币。
Related Articles
Asia
JCET's Q1 Profit Jumps 43%, Revenue Slips 2%
JCET's (SHA:600584) net profit attributable to shareholders in the first quarter jumped 43% to 290.3 million yuan from 203.4 million yuan a year earlier, according to a Shanghai bourse filing on Wednesday.Earnings per share rose 45% year on year to 0.16 yuan from 0.11 yuan.Operating revenue slipped 1.8% to 9.17 billion yuan from 9.34 billion yuan in the preceding year.The shares of the Chinese integrated circuit manufacturer dropped less than 3% during midday trade.
$SHA:600584
Asia
Update: G8 Education to Suspend Operation of Around 40 Centers, Shares Reach 16-Year Low
(Updates to add the stock movement in the sixth paragraph)G8 Education (ASX:GEM) plans to suspend the operation of around 40 of its centers as a result of an assessment of its network, according to a Wednesday Australian bourse filing.It will transition customers to one of the nearby centers and, where possible, redeploy team members. The firm will then consider longer-term options for those centers, including lease surrender, divestment, or other alternatives.The firm will also reorganize its support office structure and reduce its cost base.Its current spot occupancy as of April 24 came in at 56.4%, down 7% year-over-year, while year-to-date occupancy was 56.1%, down 7.9% versus the prior corresponding period.Occupancy across the early childhood education and care sector is lower compared to previous years due to sustained affordability pressures, falling birth rates, increased long-day care supply, and confidence impacted by serious child safety incidents, the filing noted.Its shares fell 25% in recent trading on Wednesday, earlier reaching a 16-year low.
$ASX:GEM
Asia
Fosun Pharmaceutical Reports 14% Higher Profit in Q1
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.
$HKG:2196$SHA:600196